JCO at ESMO 2026: Phase 2 Neoadjuvant Cemiplimab in CSCC: Final Analysis

What long-term outcomes can be achieved with neoadjuvant cemiplimab, and how does immunotherapy reshape the treatment landscape for advanced cutaneous squamous cell carcinoma? Host Dr. Davide Soldato interviews Dr. Neil Gross on his simultaneous publication presented at ESMO 2026 "A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II–IV Cutaneous Squamous Cell Carcinoma: Final Analysis." They explore the clinical rationale, long-term survival and durability outcomes, and the profound impact of this approach on surgical morbidity and patient quality of life. Dr. Gross also shares insights on how these results are paving the way for ongoing randomized trials and the future of treatment personalization in advanced skin cancers.